Health Care • Biotechnology: Pharmaceutical Preparations
$151.58 ▲ +4.11
(+2.79%)
MKT CAP: $2.18B • VOL: 343.0K
52W L $72 52W H $161
ROARABLE / RQD
D • 46/100
PIOTROSKI
2 / 9
PVLA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $42.8M |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$38.6M | -$14.1M | -$11.9M |
| Operating Margin % | — | — | -27.7% |
| Net Income (GAAP) | -$41.7M | -$17.4M | $18.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$25.0M | -$10.8M | -$13.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$25.0M | -$10.8M | -$13.7M |
| FCF Margin % | — | — | -32.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $58.0M | $83.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $28.0M | $62.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PVLA.